by | Apr 29, 2024 | Publications
Int J Hematol Oncol Stem Cell Res. 2024 Jan 1;18(1):64-74. doi: 10.18502/ijhoscr.v18i1.14745. ABSTRACT Background: To assess the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients with acute renal failure....
by | Apr 29, 2024 | Publications
Indian J Nephrol. 2024 Mar-Apr;34(2):205. doi: 10.4103/ijn.ijn_234_23. Epub 2023 Sep 29. NO ABSTRACT PMID:38681022 | PMC:PMC11044661 | DOI:10.4103/ijn.ijn_234_23
by | Apr 29, 2024 | Publications
Mol Biol Rep. 2024 Apr 29;51(1):587. doi: 10.1007/s11033-024-09517-2. ABSTRACT BACKGROUND: Patients with multiple myeloma exhibit malignant osteolytic bone disease due to excessive osteoclast formation and function. We recently identified that osteoclastogenic...
by | Apr 29, 2024 | Publications
Clin Exp Med. 2024 Apr 29;24(1):90. doi: 10.1007/s10238-024-01347-7. ABSTRACT Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the rapid proliferation of malignant plasma cells within the bone marrow. Standard therapies often fail due to...
by | Apr 28, 2024 | Publications
Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461. ABSTRACT The clinical signs of multiple myeloma, a plasma cell (PC) dyscrasia, include bone loss, renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of malignant PCs within the...
by | Apr 28, 2024 | Publications
J Pers Med. 2024 Mar 29;14(4):360. doi: 10.3390/jpm14040360. ABSTRACT The benefit of associating anti-CD38 monoclonal antibodies to proteasome inhibitor (PI)/immunomodulatory agent (IA) and dexamethasone in the treatment of patients with relapsed or refractory...
